Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBUMINUS albumin dose reduction during large-volume paracentesis in cirrhosis
2026-526167-38-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of albumin (human) in Cirrhosis and ascites (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Proportion of patients with at least one overt liver-related decompensation event by 52 weeks. Planned start Nov 2026; status: authorised.
02
Drugs
albumin (human)
03
Conditions
Cirrhosisascites
Beyond the preview
Go deeper on 2026-526167-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526167-38-00.